New drug SKB571 takes on recurrent head and neck cancer
NCT ID NCT07668154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SKB571 (a drug)
- What this could lead to
- If it works, this could provide a new treatment option for people with head and neck cancer that has come back or spread.
- What could go wrong
- This is an early Phase II trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Oriental Hospital
Shanghai, China
-
West China Hospital, Sichuan University
Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- New drug combo aims to shrink oral cancers before surgery
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New combo therapy aims to fight returning head and neck cancer